What MOTS-c is and how it works
Almost every protein in a human cell is encoded in the nucleus. Mitochondria are the exception: they carry their own small circular genome, a remnant of the bacterium that became an organelle, holding 37 genes. For decades that was assumed to be the whole inventory. It was not. Short open reading frames hide inside the mitochondrial ribosomal RNA genes and encode small peptides the cell releases. MOTS-c is the best known of them.
The name abbreviates mitochondrial open reading frame of the 12S ribosomal RNA type-c, which is simply its address in the genome. It is 16 amino acids long, it was described by Changhan Lee, Pinchas Cohen and colleagues in Cell Metabolism in 2015, and it is treated as a signal sent from the mitochondrion to the rest of the cell. That idea, that the organelle talks back rather than only taking orders, is why the field attracted attention.
The reported mechanism runs through metabolism rather than through a receptor. In cell and mouse studies MOTS-c interferes with the folate cycle at the step that feeds purine synthesis, which lets the intermediate AICAR accumulate. AICAR activates AMP-activated protein kinase, the enzyme cells use to sense a shortage of energy: when AMPK switches on, the cell burns fuel rather than storing it. Later cell work reported that MOTS-c can also move into the nucleus under metabolic stress and influence nuclear gene expression. No cell-surface receptor has been identified, which is a real gap in the account.
What the research shows for MOTS-c
This is a young field, and the honest summary is short. The literature is about a decade old, most of it comes from one research school and its collaborators, and it is almost entirely cell culture and mouse work.
In the original 2015 work, mice fed a high-fat diet and given MOTS-c resisted weight gain and the insulin resistance that normally follows, with changes in muscle glucose handling consistent with the AMPK mechanism. Later mouse studies reported better physical performance in older animals, and cell studies have described effects on glucose uptake and fatty acid oxidation. These are consistent animal findings, and they are the reason the peptide is studied. They are not human results, and mouse metabolic models have a long record of not transferring.
The human evidence, stated plainly
No controlled trial of MOTS-c as a treatment has been published: no randomised trial, no placebo group, no efficacy endpoint, in any human population. What exists in humans is measurement. The peptide can be detected in plasma and skeletal muscle, its concentration has been reported to change with age, exercise and metabolic disease, and population genetics has linked natural variation in the sequence to metabolic differences in some groups. Every one of those is an observed association. None of them tests what happens when the peptide is given to a person.
The fair position, then: a plausible mechanism, a consistent animal record, human data limited to observation, and no clinical evidence of benefit or harm. Anyone describing MOTS-c as proven in people is describing something that has not been published.
Doses used in published research
There is no validated human dose for MOTS-c, because no trial has established one. Published work describes study designs, summarised qualitatively below rather than as figures that would imply a human schedule.
| Setting | Model | Administration | What the design can show |
|---|---|---|---|
| Cell culture | Muscle, liver and other cell lines | Peptide added to the medium | Mechanism only: signalling, gene expression, glucose uptake |
| Metabolic animal studies | Mice, often on a high-fat diet | Repeated injection over weeks | Whole-animal effects on weight and insulin sensitivity |
| Ageing and exercise studies | Older mice | Repeated injection | Physical performance in an animal model |
| Human work | Volunteers and cohorts | None given: the peptide was measured, not administered | Associations with age, exercise and disease |
Animal doses in the literature are given per kilogram of body weight and vary between studies, so quoting one figure would misrepresent the range. These are laboratory study designs, recorded for reference. They are not instructions, and nothing about them translates into a human protocol.
Safety and side effects of MOTS-c
There is no human safety database for MOTS-c. That is not a formality: the usual sources, trial adverse event tables and post-authorisation reporting, do not exist for this compound.
- Animal studies. Published rodent work has not reported overt toxicity at the doses used, but those studies were short, small and built to measure metabolic endpoints rather than safety.
- Unknown in humans. Tolerability, immune response, interactions and the effect of prolonged exposure are unstudied in people.
- Endogenous does not mean harmless. A naturally occurring molecule given at pharmacological levels behaves differently from the same molecule at physiological levels.
- Material quality. With no safety data to fall back on, purity and identity carry more weight than usual. Synthesis impurities, rather than the peptide, are a plausible source of unexpected effects.
Regulatory status of MOTS-c in Europe
MOTS-c is not authorised as a medicine anywhere in the European Union. No dossier has been assessed by the European Medicines Agency, there is no brand name and no national authorisation, and it is not a permitted food supplement ingredient. It is a research chemical for laboratory use, and in the EU a medicinal product may only be placed on the market with an authorisation. Rules on possession and personal import differ between member states.
Athletes should read one point carefully. MOTS-c is not named individually on the WADA Prohibited List, but the S0 class covers pharmacological substances that no government health authority has approved for human therapeutic use, and it applies at all times, in and out of competition. A compound in this position falls squarely within that description. The list is reissued each year.
Sourcing MOTS-c and checking quality
King Peptides stocks this peptide as MOTS-c 10 mg. With no pharmaceutical equivalent and no clinical literature to anchor it, the certificate of analysis is the only meaningful evidence about what is in the vial.
Check HPLC purity of 99% or better and a mass spectrometry result at 2174.6 Da, matching the molecular panel beside this article. One detail is specific to this sequence: MOTS-c contains two methionine residues, and methionine oxidises readily. Each added oxygen shifts the mass by 16 Da, so a peak sitting 16 or 32 Da above the target is a sign of material exposed to air, warmth or light. That is the practical reason to take storage seriously, as set out in our storage and reconstitution guide; the certificate of analysis guide explains how to read the chromatogram and match the lot number. Dispatch is from the Netherlands, which keeps EU orders inside the customs union: 1–2 business days domestically, 3–5 elsewhere in the EU, nothing to clear. Parcels to non-EU countries such as the United Kingdom, Switzerland or Norway can meet import rules and duties. Packaging is neutral and tracked, and checkout requires confirmation of research use and an age of at least 18.
Frequently asked questions about MOTS-c
What makes a peptide mitochondrial-derived? It is encoded in the mitochondrial genome rather than the nuclear one. MOTS-c comes from a short reading frame inside the 12S ribosomal RNA gene, so it is present in the mitochondrial DNA of every cell. Our primer on what research peptides are covers the wider vocabulary.
Is MOTS-c proven to improve insulin sensitivity? In mice the effect is reported consistently. In humans it has never been tested in a controlled trial. The two statements are not interchangeable.
Why is it grouped with the incretin peptides? Because the research question is metabolic. The mechanism is unrelated: AMPK signalling inside the cell rather than a gut hormone receptor. The other metabolic peptides are incretin agonists with clinical trial programmes behind them.
What should a certificate of analysis show? A lot number matching the vial, HPLC purity of at least 99%, and a mass at 2174.6 Da without a large oxidised shoulder 16 Da higher.
Research use only. MOTS-c is described here for laboratory and scientific research. Research material carries no marketing authorisation, whatever the status of the molecule as a medicine elsewhere, and it is not intended for human or veterinary use. Nothing on this page is medical advice, and the dosing information above summarises published study designs. Always comply with the laws that apply in your country.